| dc.description.abstract | Genital ulcer disease by virtue of disruption of the mucosal surfaces may enhance HIV acquisition. Genital ulcer disease treatment
with resolution of the ulcers may therefore contribute in reducing the sexual acquisition of HIV.
Objectives
To determine the effects of treatment of genital ulcer disease on sexual acquisition of HIV. There were three randomized controlled trials that met our inclusion criteria recruited HIV-negative participants with chancroid (two
trials with 143 participants) and primary syphilis (one trial with 30 participants). The syphilis study, carried out in the US between
1995 and 1997, randomized participants to receive a single 2.0 g oral dose of azithromycin (11 participants); two 2.0 g oral doses of
azithromycin administered six to eight days apart (eight participants); or benzathine penicillin G administered as either 2.4 million
units intramuscular injection once or twice seven days apart (11 participants). No participant in the trial seroconverted during 12 months of follow-up. The chancroid trials, conducted in Kenya by 1990, found no significant differences in HIV seroconversion rates
during four to 12 weeks of follow-up between 400 and 200 mg single oral doses of fleroxacin (one trial, 45 participants; RR 3.00; 95%
CI 0.29 to 30.69), or between 400 mg fleroxacin and 800 mg sulfamethoxazole plus 160 mg trimethoprim (one trial, 98 participants;
RR 0.33; 95% CI 0.04 to 3.09). Adverse events reported were mild to moderate in severity, and included Jarisch-Herxheimer reactions
and gastrointestinal symptoms. The differences between the treatment arms in the incidence of adverse events were not significant.
The quality of this evidence on the effectiveness of genital ulcer disease treatment in reducing sexual acquisition of HIV, according to
GRADE methodology, is of very low quality | en |
